Details of the Drug Combinations

General Information of This Drug (ID: DM4LSPN)

Drug Name

Ibudilast DM4LSPN

Synonyms

Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine

Indication

Disease Entry	ICD 11	Status	REF
Castleman's disease	4B2Y	Approved	[1]
Alcohol dependence	6C40.2	Phase 2	[2]
Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
Methamphetamine dependence	6C46.2	Phase 2	[2]
Multiple sclerosis	8A40	Phase 2	[4]
Opioid dependence	6C43.2Z	Phase 2	[2]
Asthma	CA23	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ibudilast + Temozolomide	DCZ68RQ	Temozolomide	Glioblastoma	[6]
Ibudilast + Riluzole	DCBEAF9	Riluzole	Amyotrophic Lateral Sclerosis	[7]
------------------------------------------------------------------------------------

References

1	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. Brain. 2023 Mar 1;146(3):898-911.
6	ClinicalTrials.gov (NCT03782415) Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
7	ClinicalTrials.gov (NCT02238626) Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)